We could not find any results for:
Make sure your spelling is correct or try broadening your search.
At Metagenomi, we are creating potentially curative therapeutics using our metagenomics-powered genome editing toolbox.We believe tools with capabilities that go beyond the current technology landscape will be required in order to reach the full therapeutic potential of geno... At Metagenomi, we are creating potentially curative therapeutics using our metagenomics-powered genome editing toolbox.We believe tools with capabilities that go beyond the current technology landscape will be required in order to reach the full therapeutic potential of genome editing. By harnessing the power of metagenomics, the study of genomes recovered from uncultivated organisms in the natural environment, we are discovering and developing asuite of novel genome editing tools with the potential to make any desired therapeutic gene edit, anywhere in the human genome. Show more
- Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024 - Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 &...
Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024...
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for...
EMERYVILLE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its...
EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (“Metagenomi”), a precision genetic medicines company committed to developing curative therapeutics for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.51 | 22.9135053111 | 6.59 | 8.395 | 6.5 | 164641 | 7.10148517 | CS |
4 | -2.69 | -24.9304911956 | 10.79 | 11.01 | 6.5 | 115452 | 8.15410028 | CS |
12 | -2.15 | -20.9756097561 | 10.25 | 12.74 | 6.5 | 193290 | 10.61565032 | CS |
26 | -2.15 | -20.9756097561 | 10.25 | 12.74 | 6.5 | 193290 | 10.61565032 | CS |
52 | -2.15 | -20.9756097561 | 10.25 | 12.74 | 6.5 | 193290 | 10.61565032 | CS |
156 | -2.15 | -20.9756097561 | 10.25 | 12.74 | 6.5 | 193290 | 10.61565032 | CS |
260 | -2.15 | -20.9756097561 | 10.25 | 12.74 | 6.5 | 193290 | 10.61565032 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions